8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mortality Rate Associated with Diabetes: Outcomes From a General Practice Level Analysis in England Using the Royal College of General Practitioners (RCGP) Database Indicate Stability Over a 15 Year Period

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          Total population mortality rates have been falling and life expectancy increasing for more than 30 years. Diabetes remains a significant risk factor for premature death. Here we used the Oxford Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) practices to determine diabetes-related vs non-diabetes-related mortality rates.

          Methods

          RCGP RSC data were provided on annual patient numbers and deaths, at practice level, for those with and without diabetes across four age groups (< 50, 50–64, 65–79, ≥ 80 years) over 15 years. Investment in diabetes control, as measured by the cost of primary care medication, was also taken from GP prescribing data.

          Results

          We included 527 general practices. Over the period 2004–2019, there was no significant change in life years lost, which varied between 4.6 and 5.1 years over this period. The proportion of all diabetes deaths by age band was significantly higher in the 65–79 years age group for men and women with diabetes than for their non-diabetic counterparts. For the year 2019, 26.6% of deaths were of people with diabetes. Of this 26.6%, 18.5% would be expected from age group and non-diabetes status, while the other 8.1% would not have been expected—pro rata to nation, this approximates to approximately 40,000 excess deaths in people with diabetes vs the general population.

          Conclusion

          There remains a wide variation in mortality rate of people with diabetes between general practices in UK. The mortality rate and life years lost for people with diabetes vs non-diabetes individuals have remained stable in recent years, while mortality rates for the general population have fallen. Investment in diabetes management at a local and national level is enabling us to hold the ground regarding the life-shortening consequences of having diabetes as increasing numbers of people develop T2DM at a younger age.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Diabetes Mellitus–Related All‐Cause and Cardiovascular Mortality in a National Cohort of Adults

          Background Diabetes mellitus is a risk factor for cardiovascular disease (CVD) and has been associated with 2‐ to 4‐fold higher mortality. Diabetes mellitus–related mortality has not been reassessed in individuals receiving routine care in the United States in the contemporary era of CVD risk reduction. Methods and Results We retrospectively studied 963 648 adults receiving care in the US Veterans Affairs Healthcare System from 2002 to 2014; mean follow‐up was 8 years. We estimated associations of diabetes mellitus status and hemoglobin A1c (HbA1c) with all‐cause and CVD mortality using covariate‐adjusted incidence rates and multivariable Cox proportional hazards regression. Of participants, 34% had diabetes mellitus. Compared with nondiabetic individuals, patients with diabetes mellitus had 7.0 (95% CI, 6.7–7.4) and 3.5 (95% CI, 3.3–3.7) deaths/1000‐person‐years higher all‐cause and CVD mortality, respectively. The age‐, sex‐, race‐, and ethnicity‐adjusted hazard ratio for diabetes mellitus–related mortality was 1.29 (95% CI, 1.28–1.31), and declined with adjustment for CVD risk factors (hazard ratio, 1.18 [95% CI, 1.16–1.19]) and glycemia (hazard ratio, 1.03 [95% CI, 1.02–1.05]). Among individuals with diabetes mellitus, CVD mortality increased as HbA1c exceeded 7% (hazard ratios, 1.11 [95% CI, 1.08–1.14], 1.25 [95% CI, 1.22–1.29], and 1.52 [95% CI, 1.48–1.56] for HbA1c 7%–7.9%, 8%–8.9%, and ≥9%, respectively, relative to HbA1c 6%–6.9%). HbA1c 6% to 6.9% was associated with the lowest mortality risk irrespective of CVD history or age. Conclusions Diabetes mellitus remains significantly associated with all‐cause and CVD mortality, although diabetes mellitus–related excess mortality is lower in the contemporary era than previously. We observed a gradient of mortality risk with increasing HbA1c >6% to 6.9%, suggesting HbA1c remains an informative predictor of outcomes even if causality cannot be inferred.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis

            Objective To examine the relationship between glycated haemoglobin A1c (HbA1c) levels and the risk of cardiovascular outcomes and all-cause mortality based on data from observational studies and to determine the optimal levels of HbA1c for preventing cardiovascular events and/or mortality in diabetic and non-diabetic populations. Review methods We systematically searched Medline, Embase, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews and Web of Science databases, from inception to July 2016, for observational studies addressing the association of HbA1c levels with mortality and cardiovascular outcomes. Random effects models were used to compute pooled estimates of HR and respective 95% CI for all-cause mortality, cardiovascular mortality and risk of cardiovascular events, separately for people with and without diabetes. Results Seventy-four published studies were included in the systematic review, but only 46 studies could be incorporated in the meta-analysis. In both diabetic and non-diabetic populations, there was an increase in the risk of all-cause mortality when HbA1c levels were over 8.0% and 6.0%, respectively. The highest all-cause mortality in people with diabetes was HbA1c above 9.0% (HR=1.69; 95% CI 1.09 to 2.66) and in those without diabetes was HbA1c above 6.0% (HR=1.74; 95% CI 1.38 to 2.20). However, both diabetic and non-diabetic populations with lower HbA1c levels (below 6.0% HR=1.57; 95% CI 1.14 to 2.17 and below 5.0% HR=1.19; 95% CI 1.04 to 1.36, respectively) had higher all-cause mortality. Similar pooled estimates were found when cardiovascular mortality was the outcome variable. Conclusion HbA1c is a reliable risk factor of all-cause and cardiovascular mortality in both diabetics and non-diabetics. Our findings establish optimal HbA1c levels, for the lowest all-cause and cardiovascular mortality, ranging from 6.0% to 8.0% in people with diabetes and from 5.0% to 6.0% in those without diabetes.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84).

              To estimate the immediate and long-term inpatient and non-inpatient costs for Type 2 diabetes-related complications.
                Bookmark

                Author and article information

                Contributors
                adrian.heald@manchester.ac.uk
                Journal
                Diabetes Ther
                Diabetes Ther
                Diabetes Therapy
                Springer Healthcare (Cheshire )
                1869-6953
                1869-6961
                21 February 2022
                21 February 2022
                March 2022
                : 13
                : 3
                : 505-516
                Affiliations
                [1 ]GRID grid.5379.8, ISNI 0000000121662407, The School of Medicine and Manchester Academic Health Sciences Centre, Manchester University, ; Manchester, UK
                [2 ]GRID grid.415721.4, ISNI 0000 0000 8535 2371, Department of Endocrinology and Diabetes, , Salford Royal Hospital, ; Salford, M6 8HD UK
                [3 ]Res Consortium, Andover, Hampshire UK
                [4 ]GRID grid.416394.d, ISNI 0000 0004 0400 720X, Black Country Pathology Services, , Walsall Manor Hospital, ; Walsall, UK
                [5 ]GRID grid.411306.1, ISNI 0000 0000 8728 1538, Biochemistry Department, Faculty of Dentistry, , Tripoli University, ; Tripoli, Libya UK
                [6 ]Marina Nacional 162, Anáhuac Secc, Miguel Hidalgo, 11320 Mexico City, Mexico
                [7 ]GRID grid.7372.1, ISNI 0000 0000 8809 1613, Warwick Medical School, , University of Warwick, ; Warwick, UK
                [8 ]GRID grid.507581.e, ISNI 0000 0001 0033 9432, The Ipswich Diabetes Centre and Research Unit, Ipswich Hospital NHS Trust, ; Colchester, Essex UK
                [9 ]GRID grid.4991.5, ISNI 0000 0004 1936 8948, Nuffield Department of Primary Care Health Sciences, , University of Oxford, ; Oxford, UK
                [10 ]GRID grid.5475.3, ISNI 0000 0004 0407 4824, Clinical and Experimental Medicine, , University of Surrey, ; Guildford, UK
                Author information
                http://orcid.org/0000-0002-9537-4050
                Article
                1215
                10.1007/s13300-022-01215-1
                8934837
                35187627
                a15d2e90-5794-436e-a44a-6f7c66659b26
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 28 November 2021
                : 28 January 2022
                Categories
                Original Research
                Custom metadata
                © The Author(s) 2022

                Endocrinology & Diabetes
                diabetes,mortality,royal college of general practitioners,general practice,trend

                Comments

                Comment on this article